Nuvation Bio Schedules 2025 Financial Results and Business Update for March 2
Event summary
- Nuvation Bio will report Q4 and full-year 2025 financial results on March 2, 2026.
- The company will host a conference call and webcast at 4:30 p.m. ET.
- Nuvation Bio's pipeline includes taletrectinib (IBTROZI®), safusidenib, NUV-868, and a drug-drug conjugate program.
- Founded in 2018 by David Hung, M.D., the company has offices in New York, San Francisco, Boston, and Shanghai.
The big picture
Nuvation Bio's upcoming financial results and business update come at a critical juncture for the oncology-focused biopharma company. As it navigates a competitive landscape, the performance of its diverse pipeline—particularly taletrectinib and safusidenib—will be key indicators of its strategic direction. The company's ability to translate its scientific advancements into commercial success will be closely watched by investors and industry analysts.
What we're watching
- Pipeline Progress
- How the advancement of taletrectinib, safusidenib, and NUV-868 will impact Nuvation Bio's market position.
- Financial Performance
- Whether Nuvation Bio can sustain growth given the competitive oncology landscape.
- Regulatory Approvals
- The pace at which Nuvation Bio secures regulatory approvals for its key candidates.
Related topics